Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

504 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
In situ expression of tumor antigens by messenger RNA-electroporated dendritic cells in lymph nodes of melanoma patients.
Schuurhuis DH, Verdijk P, Schreibelt G, Aarntzen EH, Scharenborg N, de Boer A, van de Rakt MW, Kerkhoff M, Gerritsen MJ, Eijckeler F, Bonenkamp JJ, Blokx W, van Krieken JH, Boerman OC, Oyen WJ, Punt CJ, Figdor CG, Adema GJ, de Vries IJ. Schuurhuis DH, et al. Among authors: van de rakt mw, van krieken jh. Cancer Res. 2009 Apr 1;69(7):2927-34. doi: 10.1158/0008-5472.CAN-08-3920. Epub 2009 Mar 24. Cancer Res. 2009. PMID: 19318559
Intratumoral recombinant human interleukin-12 administration in head and neck squamous cell carcinoma patients modifies locoregional lymph node architecture and induces natural killer cell infiltration in the primary tumor.
van Herpen CM, van der Laak JA, de Vries IJ, van Krieken JH, de Wilde PC, Balvers MG, Adema GJ, De Mulder PH. van Herpen CM, et al. Among authors: van der laak ja, van krieken jh. Clin Cancer Res. 2005 Mar 1;11(5):1899-909. doi: 10.1158/1078-0432.CCR-04-1524. Clin Cancer Res. 2005. PMID: 15756016 Clinical Trial.
Intratumoral rhIL-12 administration in head and neck squamous cell carcinoma patients induces B cell activation.
van Herpen CM, van der Voort R, van der Laak JA, Klasen IS, de Graaf AO, van Kempen LC, de Vries IJ, Boer TD, Dolstra H, Torensma R, van Krieken JH, Adema GJ, De Mulder PH. van Herpen CM, et al. Among authors: van kempen lc, van der laak ja, van der voort r, van krieken jh. Int J Cancer. 2008 Nov 15;123(10):2354-61. doi: 10.1002/ijc.23756. Int J Cancer. 2008. PMID: 18729197 Free article. Clinical Trial.
Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.
Tol J, Dijkstra JR, Klomp M, Teerenstra S, Dommerholt M, Vink-Börger ME, van Cleef PH, van Krieken JH, Punt CJ, Nagtegaal ID. Tol J, et al. Among authors: van krieken jh, van cleef ph. Eur J Cancer. 2010 Jul;46(11):1997-2009. doi: 10.1016/j.ejca.2010.03.036. Epub 2010 Apr 21. Eur J Cancer. 2010. PMID: 20413299 Clinical Trial.
Tetraspanin CD37 protects against the development of B cell lymphoma.
de Winde CM, Veenbergen S, Young KH, Xu-Monette ZY, Wang XX, Xia Y, Jabbar KJ, van den Brand M, van der Schaaf A, Elfrink S, van Houdt IS, Gijbels MJ, van de Loo FA, Bennink MB, Hebeda KM, Groenen PJ, van Krieken JH, Figdor CG, van Spriel AB. de Winde CM, et al. Among authors: van der schaaf a, van den brand m, van spriel ab, van houdt is, van de loo fa, van krieken jh. J Clin Invest. 2016 Feb;126(2):653-66. doi: 10.1172/JCI81041. Epub 2016 Jan 19. J Clin Invest. 2016. PMID: 26784544 Free PMC article.
504 results